Locally Advanced Pancreatic Cancer: A Review of Local Ablative Therapies
AbstractPancreatic cancer is typically characterized by its aggressive tumor growth and dismal prognosis. Approximately 30% of patients with pancreatic cancer present with locally advanced disease, broadly defined as having a tumor-to-artery interface >180°, having an unreconstructable portal vein or superior mesenteric vein and no signs of metastatic disease. These patients are currently designated to palliative systemic chemotherapy, though median overall survival remains poor (approximately 11 months). Therefore, several innovative local therapies have been investigated as new treatment options for locally advanced pancreatic cancer (LAPC). This article provides an overview of available data with regard to morbidity and oncological outcome of novel local therapies for LAPC. View Full-Text
Share & Cite This Article
Ruarus, A.; Vroomen, L.; Puijk, R.; Scheffer, H.; Meijerink, M. Locally Advanced Pancreatic Cancer: A Review of Local Ablative Therapies. Cancers 2018, 10, 16.
Ruarus A, Vroomen L, Puijk R, Scheffer H, Meijerink M. Locally Advanced Pancreatic Cancer: A Review of Local Ablative Therapies. Cancers. 2018; 10(1):16.Chicago/Turabian Style
Ruarus, Alette; Vroomen, Laurien; Puijk, Robbert; Scheffer, Hester; Meijerink, Martijn. 2018. "Locally Advanced Pancreatic Cancer: A Review of Local Ablative Therapies." Cancers 10, no. 1: 16.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.